- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02940795
Dietary Sugars Found In Breast Milk
Maternal Transmission of Dietary Sugars in Breast Milk
The majority of pregnant women in the United States are either overweight or obese at conception with their offspring having greater adiposity at birth, a 2-fold greater risk of later obesity and neonatal insulin resistance.
Conventional wisdom holds that breast-milk composition is uniform; recently our group has questioned this. An increase in consumption of dietary sugars including fructose over the past 30 years has risen, and this has been associated with chronic metabolic and endocrine disorders and phenotypic alterations that promote obesity and diabetes. However, no prior studies have examined how maternal increases of sugars/fructose during lactation affects breast-milk composition with potential transmission to the infant. The objective of this proposal is to comprehensively assess the presence and pharmacokinetics of sugars, including fructose in human breast-milk in response to maternal consumption. The central hypothesis is that a graded, dose-response relationship be-tween maternal adiposity and sugar concentrations in breast-milk exist and that milk fructose concentrations are associated with altered body composition in the first months of life. This proposal, guided by compelling preliminary data will examine the evidence linking high intakes of milk fructose with altered metabolism and early obesity by pursuing two Specific Aims: 1) Test novel relationships between breast-milk sugars and changes in infant fat mass and 2) Characterize the pharmacokinetics of milk sugars after consuming a 20 oz. cola. These aims are significant given the intractability of obesity/diabetes and a potentially identifiable novel target, making for a clear but powerful public message to reduce sugary beverage consumption during lactation.
Study Overview
Detailed Description
One of the most highly effective preventive measures a mother can make in protecting the health of her infant and herself is to breastfeed. Despite extensive research on breast-milk, limited information beyond basic micro/macronutrient composition currently exists in the literature. Breast-milk is a complex, non-uniform biological substance. In prior studies the PI has shown significant associations be-tween non-nutritive constituents in breast-milk (e.g. IL-6, TNF-α, insulin, leptin) and body composition in infants starting at 4wks of age. The putative causal influence of breastfeeding reducing obesity is mixed with no clear probative evidence showing causal pathways. Despite many studies in this area, there are no detailed studies that have examined the potential modifying role of maternal diet, especially one high in sugars on the compositional makeup of the three largest breast-milk sugars (glucose, galactose and lactose) with none to date looking at fructose. Animal models have demonstrated that the obesogenic effect of maternal fructose consumption is transmitted to offspring via breast-milk with fructose-fed lactating dams producing offspring with double fasting insulin levels compared to control pups. This is relevant in humans because of the increase in dietary sugar consumption that has occurred in the population.
A mother/infant cohort (n=37) has been established with detailed infant phenotypic body composition (dual-energy X-ray absorptiometry) and detailed breast-milk analysis (insulin, leptin, IL-6, TNF-α but no milk sugars other than glucose) in exclusively breast feeding mothers varying widely in BMI (19 to 44 kg/m2). Sampling of breast-milk and infant body composition occurred at both 4 and 24wks. As a proof of concept, fructose was detected in breast-milk from 9 of these mothers which was significantly related to infant body fat, which is a novel finding to date and has never been reported in the literature. Building upon this prior work this study will determine the concentration and pharmacokinetics of breast-milk sugars after a test beverage is consumed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Exclusively lactating mothers
- Mothers must be 3 weeks to 6 weeks postpartum
Exclusion Criteria:
- Smoked during pregnancy or are currently smoking
- Unable to provide breast milk samples using a breast pump
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Coke cola
Exclusively lactating mothers with infants between 4-6 weeks were investigated.
Lactating mothers will be consume a 20 ounce bottle of coke cola.
|
Patients were given a 20 ounce bottle of Coke Cola.
Patients were given a 12 ounce can of Diet Rite.
|
|
Experimental: Diet Rite
Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
|
Patients were given a 20 ounce bottle of Coke Cola.
Patients were given a 12 ounce can of Diet Rite.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fructose in breast milk will be measured in human breast milk at one month.
Time Frame: One month
|
Breast milk fructose at one month will be analyzed.
|
One month
|
|
The change in fructose in breast milk from one to six months.
Time Frame: Six months
|
The potential change in breast milk fructose from one to six months will be investigated.
|
Six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breast milk fructose will be measured after the ingestion of a regular 20 ounce bottle of coke and a 12 ounce can of diet rite.
Time Frame: 6 hours.
|
After the ingestion of either a regular 20 ounce bottle of coke or a 12 ounce can of diet rite at ~ 6:00 am a milk sample will be obtained every hour until 12:00 pm.
|
6 hours.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David A Fields, PhD, University of Oklahoma
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 5297
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lactation
-
University of VirginiaUniversity of North CarolinaCompleted
-
Medela AGCompleted
-
Medela AGCompleted
-
Texas Tech University Health Sciences CenterTerminated
-
Oslo University HospitalCompleted
-
Uşak UniversityCompletedLactation | Lactation Disorder - Postpartum Condition or Complication | Lactation Disorder With Baby DeliveredTurkey
-
Chulalongkorn UniversityRecruiting
-
The Hospital for Sick ChildrenTerminated
-
Medela AGClinical Trial Unit, University Hospital Basel, SwitzerlandCompleted
Clinical Trials on Coke
-
Quadram Institute BioscienceUniversity of East Anglia; The Coca-Cola CompanyCompleted
-
The University of Tennessee, KnoxvilleWithdrawn
-
Duke-NUS Graduate Medical SchoolActive, not recruiting
-
Texas Christian UniversityCompletedOlipop | Poppi | Coca Cola - Classic | Diet CokeUnited States
-
Beth Israel Deaconess Medical CenterCompleted
-
Altamash Institute of Dental MedicineRecruitingColor StabilityPakistan